Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation Kao DP; Davis G; Aleong R; O'Connor CM; Fiuzat M; Carson PE; Anand IS; Plehn JF; Gottlieb SS; Silver MA; Lindenfeld J; Miller AB; White M; Murphy GA; Sauer W; Bristow MREur J Heart Fail 2013[Mar]; 15 (3): 324-33AIMS: There is little evidence of beta-blocker treatment benefit in patients with heart failure and reduced left ventricular ejection fraction (HFREF) and atrial fibrillation (AF). We investigated the effects of bucindolol in HFREF patients with AF enrolled in the Beta-blocker Evaluation of Survival Trial (BEST). METHODS AND RESULTS: A post-hoc analysis of patients in BEST with and without AF was performed to estimate the effect of bucindolol on mortality and hospitalization. Patients were also evaluated for treatment effects on heart rate and the influence of beta1-adrenergic receptor position 389 (beta(1)389) arginine (Arg) vs. glycine (Gly) genotypes. In the 303/2708 patients in AF, patients receiving bucindolol were more likely to achieve a resting heart rate = 80 b.p.m. at 3 months (P < 0.005) in the absence of treatment-limiting bradycardia. In AF patients and sinus rhythm (SR) patients who achieved a resting heart rate = 80 b.p.m., there were beneficial treatment effects on cardiovascular mortality/cardiovascular hospitalization [hazard ratio (HR) 0.61, P = 0.025, and 0.79, P = 0.002]. Without achieving a resting heart rate = 80 b.p.m., there were no treatment effects on events in either group. beta(1)389-Arg/Arg AF patients had nominally significant reductions in all-cause mortality/HF hospitalization and cardiovascular mortality/hospitalization with bucindolol (HR 0.23, P = 0.037 and 0.28, P = 0.039), whereas Gly carriers did not. There was no evidence of diminished heart rate response in beta(1)389-Arg homozygotes. CONCLUSION: In HFREF patients with AF, bucindolol was associated with reductions in composite HF endpoints in those who achieved a resting heart rate = 80 b.p.m. and nominally in those with the beta(1)389-Arg homozygous genotype.|Adrenergic beta-Antagonists/*therapeutic use[MESH]|Aged[MESH]|Atrial Fibrillation/complications/*drug therapy/mortality[MESH]|Case-Control Studies[MESH]|Drug Resistance/genetics[MESH]|Female[MESH]|Heart Failure/complications/*drug therapy/mortality[MESH]|Heart Rate/drug effects[MESH]|Hospitalization/statistics & numerical data[MESH]|Humans[MESH]|Kaplan-Meier Estimate[MESH]|Male[MESH]|Middle Aged[MESH]|Polymorphism, Single Nucleotide[MESH]|Propanolamines/*therapeutic use[MESH]|Proportional Hazards Models[MESH]|Receptors, Adrenergic, beta-1/genetics[MESH]|Retrospective Studies[MESH]|Treatment Outcome[MESH] |